FDA approves Genentech's Susvimo for diabetic macular edema, positive.

From Nasdaq MarketSite: 2025-02-04 20:44:21

The FDA has approved Genentech’s Susvimo for diabetic macular edema, a leading cause of vision loss in adults with diabetes. The drug is now available in the US for retina specialists and patients with DME. Susvimo was initially approved for wet age-related macular degeneration in 2021. RHHBY stock closed at $39.62, up $0.30 or 0.76%. For more health news, visit rttnews.com. Please note that opinions expressed in the article are those of the author and do not necessarily reflect Nasdaq, Inc.



Read more at Nasdaq MarketSite: Genentech : FDA Approves Susvimo For Diabetic Macular Edema Treatment